Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $30,788,695.98 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 49,018 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the completion of the transaction, the chief executive officer owned 433,372 shares in the company, valued at $272,205,286.92. This trade represents a 10.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Stock Performance

Medpace stock traded down $13.04 during mid-day trading on Wednesday, reaching $617.15. 272,881 shares of the company were exchanged, compared to its average volume of 333,111. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm’s 50-day simple moving average is $589.62 and its two-hundred day simple moving average is $513.16. The firm has a market cap of $17.22 billion, a PE ratio of 36.18, a price-to-earnings-growth ratio of 2.78 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on MEDP. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $595.20.

Hedge Funds Weigh In On Medpace

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Medpace during the second quarter worth about $1,323,047,000. Wasatch Advisors LP lifted its position in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after acquiring an additional 125,625 shares during the period. State Street Corp boosted its stake in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after acquiring an additional 28,666 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after acquiring an additional 38,760 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.